Clinical trial
Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients
NCT00316719 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316719 |
|---|---|
| Title | Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients |
| Official title | Phase III Study of Adefovir Dipivoxil Tablets in Patients With Compensated Chronic Hepatitis B -Comparative Study Against Lamivudine- |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis B |
| Intervention type | Drug |
| Interventions | LAM group, ADV group |
| Enrollment | 105 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Apr 21, 2006 |
| Last update posted | Oct 6, 2009 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: